Similar articles for PMID: 1432165

Year	Number of Results
1980	1
1981	2
1983	1
1984	1
1985	1
1986	2
1987	2
1988	3
1989	3
1990	3
1991	3
1992	3
1993	5
1994	2
1995	4
1996	3
1997	2
1998	1
1999	7
2000	3
2001	3
2002	2
2003	1
2004	1
2005	2
2007	2
2009	1
2010	1
2012	2
2013	1
2017	1
2018	1
2020	2
2021	3
2022	1
2024	0

1

PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.

Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, Graham MC, Di Resta G, Bendriem B, Daghighian F, et al. Larson SM, et al. J Nucl Med. 1992 Nov;33(11):2020-3. J Nucl Med. 1992. PMID: 1432165 Free article.

2

Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM. Ugur O, et al. Nucl Med Biol. 1996 Jan;23(1):1-8. doi: 10.1016/0969-8051(95)02001-2. Nucl Med Biol. 1996. PMID: 9004907

3

Monoclonal antibodies and neuroblastoma.

Miraldi F. Miraldi F. Semin Nucl Med. 1989 Oct;19(4):282-94. doi: 10.1016/s0001-2998(89)80021-2. Semin Nucl Med. 1989. PMID: 2678480 Review.

4

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK. Kramer K, et al. J Clin Oncol. 2007 Dec 1;25(34):5465-70. doi: 10.1200/JCO.2007.11.1807. J Clin Oncol. 2007. PMID: 18048828 Clinical Trial.

5

Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.

Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C. Dauer LT, et al. Health Phys. 2007 Jan;92(1):33-9. doi: 10.1097/01.HP.0000231583.32904.6c. Health Phys. 2007. PMID: 17164597

6

¹³¹I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors.

Zhang Y, Kupferschlaeger J, Lang P, Reischl G, Handgretinger RJ, Fougère C, Dittmann H. Zhang Y, et al. J Nucl Med. 2022 Feb;63(2):205-211. doi: 10.2967/jnumed.120.261854. Epub 2021 May 28. J Nucl Med. 2022. PMID: 34049985 Free PMC article.

7

[Nuclear medicine diagnosis and treatment in pheochromocytoma and neuroblastoma].

Fischer M. Fischer M. Bildgebung. 1987-1989;56(4):141-5. Bildgebung. 1987. PMID: 3271589 German.

8

Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK. Kramer K, et al. Med Pediatr Oncol. 2001 Jan;36(1):194-6. doi: 10.1002/1096-911X(20010101)36:1<194::AID-MPO1046>3.0.CO;2-B. Med Pediatr Oncol. 2001. PMID: 11464881

9

Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.

Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, et al. Ugur O, et al. Nucl Med Biol. 1995 Jan;22(1):87-93. doi: 10.1016/0969-8051(94)e0066-r. Nucl Med Biol. 1995. PMID: 7735175

10

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ. Cheung NK, et al. Med Pediatr Oncol. 2001 Jan;36(1):227-30. doi: 10.1002/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U. Med Pediatr Oncol. 2001. PMID: 11464891 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

72 results

Results by year